Objective: Previous reports suggest that cytokines act as potential mediators of the interaction between the immune and neuroendocrine systems, and that a proinflammatory state may be associated with bipolar disorder and schizophrenia. The aim is to compare cytokine levels in both disorders. Method: Twenty euthymic bipolar disorder patients, 53 chronic stabilized schizophrenia patients and 80 healthy controls were recruited. Subjects were all non-smokers and non-obese. Cytokines TNF-α, IL-6, and IL-10 were examined by sandwich ELISA. Results: IL-6 levels were increased in schizophrenia patients when compared to controls (p < 0.0001) and euthymic bipolar disorder patients (p < 0.0001). IL-6 levels were no different in controls compared to euthymic bipolar disorder patients (p = 0.357). IL-10 was lower in controls compared to schizophrenia patients (p = 0.001) or to bipolar disorder patients (p = 0.004). There was no significant difference in TNF-α serum levels among the groups (p = 0.284). Gender-based classification did not significantly alter these findings, and no correlation was found between the antipsychotic dose administered and cytokine levels in patients with schizophrenia. Discussion: These findings evidence a chronic immune activation in schizophrenia. Bipolar disorder seems to present an episode-related inflammatory syndrome. Increased anti-inflammatory factor IL-10 in bipolar disorder and schizophrenia suggests different patterns of inflammatory balance between these two disorders. Results further support the need to investigate cytokines as possible biomarkers of disease activity or treatment response.
Introduction
Bipolar disorder and schizophrenia share many epidemiologic and clinical features. 1 Increasing data suggest an overlap in genetic susceptibility across the two diagnoses. 2 Although their pathophysiology remains unclear, mechanisms such as oxidative stress and neuroplasticity have recently been implicated. [3] [4] [5] [6] However, these mechanisms seem to be differently involved in each disorder. 7, 8 It is well known that people with severe mental illnesses such as schizophrenia (SZ) or bipolar disorder (BD) have worse physical health outcomes and reduced life expectancy compared to the general population. 9 The excessive cardiovascular mortality associated with SZ and BD is attributed in part to an increased risk of the modifiable atherosclerotic risk factors: obesity, smoking, diabetes, hypertension and dyslipidaemia. [10] [11] [12] Inflammation is a mechanism that plays a part not only in atherosclerosis but also in different neuropsychiatric disorders, where it is involved in complex and reciprocal interactions with neurotrophins and oxidative stress. Considering these interactions, a Systemic Toxicity Index for mood episodes has recently been proposed to study neurotrophins, oxidative stress markers and inflammatory markers. 13 The action of cytokines on brain cells has been shown to be an important component of the neuroimmunological and neuroinflammatory response. Cytokines and related secretory products from immune cells communicate with the endocrine and central nervous system to modulate their collective functions.
14 In the field of mood disorders, the immune system seems to play a particularly important role. Over the years, a significant body of accumulated evidence suggests that major depression is associated with dysfunction of inflammatory mediators. 15 Patients with unipolar depression who are otherwise clinically healthy have been shown to present activated inflammatory pathways, with increased pro-inflammatory cytokines, acute-phase proteins, and increased expression of chemokines and adhesion molecules. [16] [17] [18] More recently, available evidence indicates that BD and inflammation are linked through shared genetic polymorphisms and gene expression, as well as altered cytokine levels 19 during acute episodes 20 and euthymia. 21 It has been suggested that inflammatory cytokines, particularly TNF-α, may play a critical role in changes in neuroplasticity, cell resilience and neuronal survival. 22, 23 Additionally, the combination of brain-derived neurotrophic factor (BDNF) and TNF-α serum levels has been proposed as staging biomarkers for BD. 24 Inflammatory processes have also been implicated in the pathophysiology of SZ, and different studies have focused on the role of inflammation in SZ. 25 Many observations of immune deregulation in SZ overlap with central pathophysiological mechanisms as well as with clinical manifestations of the illness. This is supported by a growing database of investigations, some of which even suggest that a subgroup of patients with SZ present the features of an autoimmune process. 26 Although this is a concept that has not yet been fully grasped, the general evidence of the existence of a pro-inflammatory state in SZ is, indeed, consistent. 23 So far, no other study has compared the levels of inflammatory markers present in BD and SZ. The examination of the different expression of physiopathological mechanisms may provide a better understanding of the etiological processes underlying both disorders, as well as new possibilities for treatment. Therefore, this study was designed to examine both euthymic patients with BD and chronic stabilized patients with SZ by comparing their cytokine levels against those from healthy controls.
Method

Subjects
This study protocol was approved by the ethics committee of the Hospital de Clínicas de Porto Alegre (HCPA), in Rio Grande do Sul, Brazil. All subjects provided their written informed consent before inclusion in the study.
We selected 53 chronically medicated and stabilized outpatients with SZ from the HCPA Schizophrenia Program, and 20 euthymic outpatients with BD from the HCPA Bipolar Disorders Program. All subjects were clinically interviewed by a trained psychiatrist. Only those patients and controls who were non-smokers and non-obese, and who did not present any major medical condition, such as atherosclerotic heart disease or diabetes, were included in the study. Obesity was defined as a body mass index (weight in kilograms/height 2 in meters) of 30 or higher. The diagnosis of BD and SZ were confirmed according to the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV). 27 The psychiatric status of patients with SZ was assessed using the Brief Psychiatric Rating Scale (BPRS) 28 and the Clinical Global Impression (CGI). 29 Only patients with BPRS scores ≤ 25 and no history of a psychiatric hospitalization over the last two years were included in the study. Mood symptoms in patients with BD were identified using the Young Mania Rating Scale (YMRS) 30 and the Hamilton Depression Rating Scale (HAMD-21). 31 Patients were considered euthymic and, therefore, able to participate in the study if both the YMRS and the HAMD scores were lower than seven. The control group consisted of 80 medication-free healthy volunteers who had no current or previous history, as well as no first-degree family member with a history of a major psychiatric disorder, including dementia or mental retardation as evaluated by the non-patient version of the Structured Clinical Interview for DSM-IV (SCID).
Serum cytokines measurement
Five milliliters of anticoagulant-free blood were drawn by venipuncture from each subject on the day of clinical interview. Serum was obtained by centrifugation at 3,000xg for 5 minutes and then kept frozen at -70°C until the assay i.e., six months later.
Serum cytokines were measured as instructed by the manufacturer, using sandwich ELISA kits for TNF-α, IL-6 and IL-10 (DuoSet, R&D Systems, Minneapolis, Minn., USA). All samples were assayed in duplicates and the same plate was used. Detection limits for these assays were set at 5pg/ml. In brief, the capture antibody (concentration provided by the manufacturer) was diluted in PBS, added to each well and left overnight at 4°C.
The plate was washed 4 times in PBS with 0.05% Tween-20 (Sigma, St. Louis, Mo., USA). The plate was blocked with 1% bovine serum albumin and incubated for 1 hour at room temperature before being washed four times with PBS and 0.05% Tween-20. The samples and standards were added, and the plate incubated overnight at 4°C. After the plate had been washed, detection antibody (concentration provided by the manufacturer) diluted in PBS was added. The plate was incubated for 2 hours at room temperature. After the plate had been washed, streptavidin (DuoSet, R&D Systems) was added and the plate incubated for 30 minutes. Finally, color reagent o-phenylenediamine (Sigma) was added to each well, and the reaction was allowed to develop in the dark for 15 minutes. The reaction was interrupted for the addition of 1 M H 2 SO 4 to each well. The absorbance was read on a plate reader at 492nm (Emax, Molecular Devices, Minneapolis, Minn., USA).
Statistical analysis
As indicated, demographic and clinical characteristics were analyzed using chi-square and ANOVA tests. Descriptive analyses are presented as mean (standard deviation, SD) or median (interquartile range), and p-values < 0.05 were considered significant. Cytokine levels showed a non-Gaussian distribution and were analyzed by applying the appropriate tests: the KruskalWallis test and the Mann-Whitney test. Relationships between variables were assessed with Spearman rank correlation coefficient. Analysis was performed using SPSS Version 16.0.
Results
The subjects' demographics and clinical characteristics are summarized in Table 1 . The three groups were not significantly different in terms of age (p = 0.115). Length of illness was longer in the group with SZ than in the group with BD (18.0, SD = 16.7 vs. 12.0, SD = 16.3, p = 0.026). Patients with SZ were predominantly male (76%), while the BD and control groups had a lower frequency of male subjects (40% in both groups). In the SZ group, 12 patients were on atypical antipsychotics, 13 on typical antipsychotics and 28 on clozapine. The BD group had 15 patients on lithium, 8 on other mood stabilizers, 10 on antipsychotics, 3 on antidepressants and 6 on benzodiazepines.
IL-6 was significantly increased in patients with SZ when compared to either the controls (p < 0.0001) or the euthymic patients with BD (p < 0.0001). IL-6 levels were no different in controls compared to euthymic BD patients (p = 0.357). IL-10 was significantly lower in controls compared to SZ (p = 0.001) or BD (p = 0.004). There was no significant difference in TNF-α serum levels among the three groups (p = 0.284) - Figure 1 . The significance did not change when patients were classified by gender (p < 0.001 and p = 0.008 for IL-6, p = 0.003 and p = 0.048 for IL-10 and p = 0.165 and p = 0.159 for TNF-α, for males and females, respectively). In patients with SZ, no correlation was found between the antipsychotic dose (in milligrams of chlorpromazine equivalents) and IL-6 (rho = -0.267, p = 0.084), IL-10 (rho = 0.031, p = 0.845) or TNF-α (rho = -0.145, p = 0.363).
Discussion
Our results are in line with those from previous reports on the presence of increased inflammatory markers in BD and SZ. However, we found significantly higher levels of pro-inflammatory cytokine IL-6 in patients with SZ compared to either patients with BD or healthy controls. Previous reports have found an association with IL-6 and acute symptomatology in BD 20 and SZ. 32 Considering that our comparison involved patients in non-acute phases of illness (euthymic BD vs. chronic SZ), our finding that there is an increased presence of IL-6 in SZ provides further evidence of a chronic immune activation and inflammatory syndrome in SZ. 23 While increased IL-6 seems to be state-dependent in BD, it seems to be a trait in patients with SZ. Nevertheless, this finding could also be explained by the longer duration of the illness in the SZ group. 33 Increased levels of TNF-α have also been previously reported in BD and SZ, and have been shown to be associated with the symptomatology of both disorders. 20, 34 Therefore, the fact that TNF-α levels were not different from those of the controls in our sample can be explained by the non-acute profile of our subjects.
Even though inflammation plays a role in both disorders, the overall balance of pro-and anti-inflammatory components is differently expressed. With this in mind, the increased levels of anti-inflammatory IL-10 found in both the SZ and BD groups, when compared to controls, should not be easily dismissed. While this could be attributed to a direct response to the elevation of IL-6 in SZ, this phenomenon could also reflect a compensatory mechanism derived from previous episodes in BD. As levels of IL-10 seem to decline with the progression of the disease, 35 the general pro-inflammatory balance in BD worsens in the later stages of the illness as the anti-inflammatory response abates.
We believe that a comparative assessment of the pathophysiological mechanisms at play in BD and SZ may provide interesting insights into the different roles played by such mechanisms in each disorder. Past comparisons have suggested that different profiles of oxidative stress, 8 neurotrophins 7 and different patterns of correlation between oxidative stress markers and neurotrophins are at play in SZ 36 and BD. 37 While different lines of evidence suggest that, in BD, we can see an episode-related deterioration pattern, it appears that, in SZ, this deterioration pattern seems to be of a chronic nature, starting at the onset of the illness. This observation brings us back to the classic differentiation between the two diagnoses based on either an episodic or a chronic-deteriorating course. In SZ, however, difficulties in defining remission in a chronically ill and stable population may not allow for a clear differentiation of state and trait effects.
The interpretation of this report and its results must take into consideration certain limitations, which include a lack of control for potential confounders. Factors such as diet and level of physical activity can substantially contribute to alterations in inflammatory markers. 11, 38, 39 The excessive incidence of medical conditions in both BD and SZ is increasingly recognized. 9 The majority of these conditions are related to inflammation, especially cardiovascular illness, obesity and insulin resistance. Even though patients with significant medical problems were excluded from our study, controlling for medical conditions, metabolic alterations and lifestyle factors was not possible.
Another potential confounder is related to the different medications used by patients with BP and SZ. It appears that mood stabilizers in general (and lithium more specifically) attenuate the pro-inflammatory milieu in BD. 19 Similarly, antipsychotics may also impact the production of cytokines. 40 Therefore, even in the absence of any correlation between cytokine levels and the dose of antipsychotic medications taken by our subjects, the confounder effect of medications cannot be ruled out.
Our findings point to the involvement of inflammatory mechanisms as a component of the pathophysiology of both BD and SZ, and provide insight into the different patterns seen in this association. We believe that studies aimed at performing a comparative analysis among disorders may provide a more thorough understanding of the inflammatory component at play in psychiatric illnesses, thus providing a basis for improved forms of intervention.
